Bionano Genomics To Acquire Purigen Biosystems To Enable Further Simplified And Accelerated Dna Isolation For Optical Genome Mapping (Ogm) And Address Difficult Sample Types In New Applications With Isotachophoresis (Itp) On The Ionic Purification System
Bionano Genomics To Acquire Purigen Biosystems To Enable Further Simplified And Accelerated Dna Isolation For Optical Genome Mapping (Ogm) And Address Difficult Sample Types In New Applications With Isotachophoresis (Itp) On The Ionic Purification System
11/28/22, 10:03 PM
Location
san diegoIndustry
bioinformatics
genetics
biotechnology
health care
software
biotechnology
Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that it has entered into a definitive agreement to acquire Purigen Biosystems, Inc. (Purigen), a company that develops and commercializes automated nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology, which was licensed exclusively from Stanford and developed by Purigen. Purigen’s ITP technology is a solution-based purification approach and therefore different from protocols in routine use today, which tend to rely on binding to a matrix, washing and then removal from the matrix. Those protocols are less efficient at capturing molecules from dilute solutions or from samples with small amounts of cells and often result in shorter average lengths of DNA than what optical genome mapping (OGM) requires. The transaction is expected to accelerate the adoption of OGM due to anticipated improvements in its ultra high molecular weight (UHMW) DNA sample preparation workflow.
Company Info
Location
9540 towne centre drive
San Diego, California, United States
Company info
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com.